A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer?s Disease (Prodromal AD)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Verubecestat (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms APECS
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

07 Jun 2019 This trial has been completed in Finland, according to European Clinical Trials Database
05 Jun 2019 This trial has been completed in Germany, according to European Clinical Trials Database.
11 Apr 2019 Interim results published in the New England Journal of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight